TENAX THERAPEUTICS, INC. (TENX) Stock Analysis — March 2026 Rating, Price, and Forecast
Company Overview — What Does TENAX THERAPEUTICS, INC. Do?
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina. TENAX THERAPEUTICS, INC. (TENX) is classified as a micro-cap stock in the Manufacturing sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Christopher T. Giordano and employs approximately 9 people, headquartered in Morrisville, North Carolina. With a market capitalization of $0, TENX is one of the notable companies in the Manufacturing sector.
TENAX THERAPEUTICS, INC. (TENX) Stock Rating — Strong Buy (March 2026)
As of March 2026, TENAX THERAPEUTICS, INC. receives a Strong Buy rating with a composite score of 82.9/100 and 5 out of 5 stars from the Blank Capital Research quantitative model.TENX ranks #845 out of 7,333 stocks in our coverage universe. Within the Manufacturing sector, TENAX THERAPEUTICS, INC. ranks #338 of 1931 stocks, placing it in the top quartile of its Manufacturing peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
TENX Stock Price and 52-Week Range
TENAX THERAPEUTICS, INC. (TENX) currently trades at $11.40. The stock lost $0.22 (1.9%) in the most recent trading session. Recent trading volume was 62K shares, suggesting relatively thin trading activity.
Is TENX Overvalued or Undervalued? — Valuation Analysis
TENAX THERAPEUTICS, INC. (TENX) carries a value factor score of 50/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The price-to-book ratio stands at 0.78x, versus the sector average of 2.40x. The price-to-sales ratio is 4.52x, compared to 2.28x for the average Manufacturing stock.
Overall, TENX's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
TENAX THERAPEUTICS, INC. Profitability — ROE, Margins, and Quality Score
TENAX THERAPEUTICS, INC. (TENX) earns a quality factor score of 25/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -26.8%, compared to the Manufacturing sector average of -5.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -25.1% versus the sector average of -1.9%.
The operating margin is 50.0% (sector: 0.7%). Net profit margin stands at -2.9%, versus -1.0% for the average Manufacturing stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
TENX Debt, Balance Sheet, and Financial Health
TENAX THERAPEUTICS, INC. has a debt-to-equity ratio of 7.0%, compared to the Manufacturing sector average of 20.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 15.00x, indicating strong short-term liquidity.
TENX has a beta of 0.25, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for TENAX THERAPEUTICS, INC. is 59/100, reflecting average volatility within the normal range for its sector.
TENAX THERAPEUTICS, INC. Revenue and Earnings History — Quarterly Trend
In TTM 2026, TENAX THERAPEUTICS, INC. reported revenue of $17M and earnings per share (EPS) of $-0.40. Net income for the quarter was $-26M. Operating income came in at $-20M.
In Q3 2025, TENAX THERAPEUTICS, INC. reported revenue of $0 and earnings per share (EPS) of $-0.40. Net income for the quarter was $-16M. Operating income came in at $-17M.
In Q1 2025, TENAX THERAPEUTICS, INC. reported revenue of $0 and earnings per share (EPS) of $-0.28. Net income for the quarter was $-10M. Operating income came in at $-11M.
In FY 2024, TENAX THERAPEUTICS, INC. reported revenue of $0 and earnings per share (EPS) of $-1.15. Net income for the quarter was $-18M. Operating income came in at $-19M.
Over the past 8 quarters, TENAX THERAPEUTICS, INC. has demonstrated a growth trajectory, with revenue expanding from $16M to $17M. Investors analyzing TENX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
TENX Dividend Yield and Income Analysis
TENAX THERAPEUTICS, INC. (TENX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Manufacturing dividend stocks may want to explore other Manufacturing stocks or use the stock screener to filter by dividend yield.
TENX Momentum and Technical Analysis Profile
TENAX THERAPEUTICS, INC. (TENX) has a momentum factor score of 87/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 49/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 45/100 reflects moderate short selling activity.
TENX vs Competitors — Manufacturing Sector Ranking and Peer Comparison
Within the Manufacturing sector, TENAX THERAPEUTICS, INC. (TENX) ranks #338 out of 1931 stocks based on the Blank Capital composite score. This places TENX in the top quartile of all Manufacturing stocks in our coverage universe. Key competitors and sector peers include INTERPARFUMS INC (IPAR) with a score of 94.5/100, BK Technologies Corp (BKTI) with a score of 91.7/100, Fitell Corp (FTEL) with a score of 90.7/100, Adicet Bio, Inc. (ACET) with a score of 86.8/100, and Park Ha Biological Technology Co., Ltd. (BYAH) with a score of 85.0/100.
Comparing TENX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full TENX vs S&P 500 (SPY) comparison to assess how TENAX THERAPEUTICS, INC. stacks up against the broader market across all factor dimensions.
TENX Next Earnings Date
No upcoming earnings date has been announced for TENAX THERAPEUTICS, INC. (TENX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy TENX? — Investment Thesis Summary
The bull case for TENAX THERAPEUTICS, INC. rests on several quantitative strengths. The quality score of 25/100 flags below-average profitability. Price momentum is positive at 87/100, suggesting the trend favors buyers.
In summary, TENAX THERAPEUTICS, INC. (TENX) earns a Strong Buy rating with a composite score of 82.9/100 as of March 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on TENX stock.
Related Resources for TENX Investors
Explore more research and tools: TENX vs S&P 500 comparison, top Manufacturing stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare TENX head-to-head with peers: TENX vs IPAR, TENX vs BKTI, TENX vs FTEL.